Long-acting antiretrovirals and HIV treatment adherence. [Review]
Long-acting antiretrovirals and HIV treatment adherence. [Review]
- 2023
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART. Copyright © 2023 Elsevier Ltd. All rights reserved.
English
2352-3018
10.1016/S2352-3018(23)00051-6 [doi] S2352-3018(23)00051-6 [pii]
*Anti-HIV Agents
*HIV Infections
Anti-Retroviral Agents/tu [Therapeutic Use]
HIV Infections/dt [Drug Therapy]
HIV Infections/et [Etiology]
Humans
Injections, Intramuscular/ae [Adverse Effects]
Rilpivirine/ae [Adverse Effects]--Automated
MedStar Washington Hospital Center
Obstetrics and Gynecology
Journal Article
Research Support, N.I.H., Extramural
Review
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART. Copyright © 2023 Elsevier Ltd. All rights reserved.
English
2352-3018
10.1016/S2352-3018(23)00051-6 [doi] S2352-3018(23)00051-6 [pii]
*Anti-HIV Agents
*HIV Infections
Anti-Retroviral Agents/tu [Therapeutic Use]
HIV Infections/dt [Drug Therapy]
HIV Infections/et [Etiology]
Humans
Injections, Intramuscular/ae [Adverse Effects]
Rilpivirine/ae [Adverse Effects]--Automated
MedStar Washington Hospital Center
Obstetrics and Gynecology
Journal Article
Research Support, N.I.H., Extramural
Review